{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:53:22Z","timestamp":1791604402658,"version":"4.3.4"},"reference-count":26,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Daratumumab became publicly available in Australia in 2021 in combination with bortezomib and dexamethasone (DVd), as a second\u2010line (2L) therapy for multiple myeloma (MM). We evaluated real\u2010world persistence to any MM treatment after first relapse before and after DVd availability using the Pharmaceutical Benefits Scheme 10% sample dataset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dispensing records for adults receiving 2L MM treatment from January 2018 to December 2020 (Period 1) and January 2021 to April 2025 (Period 2) were analyzed using Kaplan\u2013Meier to determine treatment persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Eighty patients were included in Period 1 and 290 in Period 2. Median treatment persistence was longer in Period 2 (15 months) than Period 1 (9.8 months) (hazard ratios [HRs]: 0.46; 99.9% CI: 0.23\u20130.90;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Treatment persistence in patients who progressed within 18 months on first\u2010line therapy was longer in Period 2 (13 months) than Period 1 (9.2 months) (HR: 0.53; 95% CI: 0.34\u20130.81;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.01). The Period 2 lenalidomide\u2010refractory cohort (\n                      <jats:italic>n<\/jats:italic>\n                      = 78) demonstrated a median persistence of 11 months (95% CI: 8.3\u201323 months). The number of lenalidomide\u2010refractory patients in Period 1 (\n                      <jats:italic>n<\/jats:italic>\n                      = 11) was insufficient for comparative analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The observed improvements in treatment persistence among patients with MM including those refractory to lenalidomide, following reimbursement\u2010driven availability of DVd, indicate meaningful clinical benefit in routine practice after the introduction of novel therapies, and underscores the need for sustained access to diverse and effective treatment options for relapsed MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>\n                      <jats:bold>Trial Registration<\/jats:bold>\n                      : The authors have confirmed clinical trial registration is not needed for this submission.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70377","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:18:56Z","timestamp":1787307536000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Persistence to Multiple Myeloma Treatments Given at First Relapse\u2014Results From the Australian Real\u2010World OPTIMISE Study"],"prefix":"10.1002","volume":"7","author":[{"given":"Felix","family":"Buescher","sequence":"first","affiliation":[{"name":"Janssen\u2010Cilag Pty Ltd.  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Su","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Pty Ltd.  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Waterhouse","sequence":"additional","affiliation":[{"name":"Model Solutions Pty Ltd.  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cletus","family":"Pinto","sequence":"additional","affiliation":[{"name":"Janssen\u2010Cilag Pty Ltd.  Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83630-x"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52366"},{"key":"e_1_2_13_4_1","unstructured":"H.Quach H. M.Prince andS.Harrison \u201cClinical Practice Guideline Multiple Myeloma \u201dMedical Scientific Advisory Group (MSAG) and Myeloma Australia. (2022):1\u201351. Accessed 18 August 2025 https:\/\/myeloma.org.au\/wp\u2010content\/uploads\/2022\/09\/MSAG_Myeloma\u2010Clinical\u2010Practice\u2010Guideline\u20102022_Final\u20101.pdf."},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24131"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-726703"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2022.13.5.11"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.09.623"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02734"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e19135"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9064"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18703"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05443-8"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2021_201113N1223"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-015-1616-8"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.23889\/ijpds.v6i1.1418"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.12.012"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.21310"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3756"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010155"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.1058"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.826342"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04857-0"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01956-w"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15245846"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70377","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70377","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:42:51Z","timestamp":1791603771000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1002\/jha2.70377"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70377","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2026-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70377"}}